Bortezomib remains a cornerstone treatment for multiple myeloma and mantle cell lymphoma, and Chicago's Northwestern Memorial and University of Chicago Medicine manage significant patient volumes requiring this proteasome inhibitor. Bortenat 3.5mg provides identical treatment at significantly reduced institutional cost.
Bortenat is given subcutaneously or intravenously, with subcutaneous administration now preferred due to lower peripheral neuropathy rates while maintaining equivalent efficacy. Standard dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle.
Chicago hospital pharmacies seeking cost-effective Bortezomib procurement can access Bortenat with full WHO-GMP documentation|
FAQ: What is peripheral neuropathy and why does
Bortenat cause it? Peripheral neuropathy
refers to nerve damage typically affecting hands and feet, causing tingling,
numbness, or pain. Bortezomib's mechanism of inhibiting the proteasome can
also disrupt normal nerve cell function. Risk is meaningfully lower with
subcutaneous administration than IV, which is why this route is preferred.
Symptoms often improve after treatment ends. |
